The recently launched COSIRA-II trial is assessing the NeoVasc Reducer device for treating severe refractory angina in patients ineligible for revascularization.
The multisociety document broadens the definition of chest pain and recommends against additional acute testing if ECG and high-sensitivity troponin are negative.
Many patients and doctors do not fully understand the risks and benefits of PCI, even when presented with the evidence, and this makes informed consent challenging. Michael Rothberg, MD, MPH, explains why the best approach is shared decision-making.
The trial’s new health status analysis gives even more reason to consider CABG the preferred revascularization strategy for patients with anatomically complex three-vessel or left main disease.